Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CD19/BCMA Targeted CAR T-Cells by Shanghai YaKe Biotechnology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
CD19/BCMA Targeted CAR T-Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Acute Lymphocytic...
AT-19 by Shanghai YaKe Biotechnology for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...
AT-19 by Shanghai YaKe Biotechnology for Follicular Lymphoma: Likelihood of Approval
AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Follicular Lymphoma. According to GlobalData,...
AT-19 by Shanghai YaKe Biotechnology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
AT-19 by Shanghai YaKe Biotechnology for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...
BCMA Targeted CAR T-Cells by Shanghai YaKe Biotechnology for Relapsed Multiple Myeloma: Likelihood of Approval
BCMA Targeted CAR T-Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase I for Relapsed Multiple...
BCMA Targeted CAR T-Cells by Shanghai YaKe Biotechnology for Refractory Multiple Myeloma: Likelihood of Approval
BCMA Targeted CAR T-Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase I for Refractory Multiple...